Reducing the dose of a Pfizer COVID-19 booster vaccine can elicit a comparable immune response in adults compared to a full dose with fewer side effects, new research has found.
Led by the Murdoch Institute and the National Centre for Communicable Diseases in Mongolia, the study is the first to assess and compare widely used COVID-19 vaccines in low- and middle-income countries.
The research involved 601 participants over 18 years old from Mongolia who had previously received AstraZeneca or Sinopharm COVID-19 shots.
Murdoch Institute’s Professor Kim Mulholland said they found that reduced doses of the Pfizer booster produced a non-inferior immune response.
“Fractional dosing may improve COVID-19 booster acceptability and uptake and reduce the per-dose cost of COVID-19 booster programs,” he said.
Read Full Article Here